Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma
-
Published:2023-09-25
Issue:9
Volume:14
Page:
-
ISSN:2041-4889
-
Container-title:Cell Death & Disease
-
language:en
-
Short-container-title:Cell Death Dis
Author:
Bassot Arthur, Dragic Helena, Haddad Sarah Al, Moindrot Laurine, Odouard Soline, Corlazzoli Francesca, Marinari Eliana, Bomane Alexandra, Brassens Augustin, Marteyn Antoine, Hibaoui Youssef, Petty Tom J., Chalabi-Dchar Mounira, Larrouquere Louis, Zdobnov Evgeny M.ORCID, Legrand Noémie, Tamburini Jérôme, Lincet Hubert, Castets MarieORCID, Yebra Mayra, Migliorini Denis, Dutoit Valérie, Walker Paul R.ORCID, Preynat-Seauve Olivier, Dietrich Pierre-Yves, Cosset ÉrikaORCID
Abstract
AbstractGlioblastoma (GBM) is a deadly and the most common primary brain tumor in adults. Due to their regulation of a high number of mRNA transcripts, microRNAs (miRNAs) are key molecules in the control of biological processes and are thereby promising therapeutic targets for GBM patients. In this regard, we recently reported miRNAs as strong modulators of GBM aggressiveness. Here, using an integrative and comprehensive analysis of the TCGA database and the transcriptome of GBM biopsies, we identified three critical and clinically relevant miRNAs for GBM, miR-17-3p, miR-222, and miR-340. In addition, we showed that the combinatorial modulation of three of these miRNAs efficiently inhibited several biological processes in patient-derived GBM cells of all these three GBM subtypes (Mesenchymal, Proneural, Classical), induced cell death, and delayed tumor growth in a mouse tumor model. Finally, in a doxycycline-inducible model, we observed a significant inhibition of GBM stem cell viability and a significant delay of orthotopic tumor growth. Collectively, our results reveal, for the first time, the potential of miR-17-3p, miR-222 and miR-340 multi-targeting as a promising therapeutic strategy for GBM patients.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology
Reference70 articles.
1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109. 2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96. 3. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110. 4. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462–77. 5. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004;64:6503–10.
|
|